JP7784430B2 - 新規化合物 - Google Patents

新規化合物

Info

Publication number
JP7784430B2
JP7784430B2 JP2023537723A JP2023537723A JP7784430B2 JP 7784430 B2 JP7784430 B2 JP 7784430B2 JP 2023537723 A JP2023537723 A JP 2023537723A JP 2023537723 A JP2023537723 A JP 2023537723A JP 7784430 B2 JP7784430 B2 JP 7784430B2
Authority
JP
Japan
Prior art keywords
acrylamide
methyl
alkyl
fluoro
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023537723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539694A (ja
JP2023539694A5 (cg-RX-API-DMAC10.html
Inventor
ミラー ニール
ラター リチャード
クラゴウスキ ジャン
モーフィー リチャード
ラドゥワヘッティ タミー
マクリーン ジョン
モログル ムスタファ
タルボット エリック
ローリー マイケル
Original Assignee
エヌアールジー セラピューティクス エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヌアールジー セラピューティクス エルティーディー filed Critical エヌアールジー セラピューティクス エルティーディー
Publication of JP2023539694A publication Critical patent/JP2023539694A/ja
Publication of JP2023539694A5 publication Critical patent/JP2023539694A5/ja
Application granted granted Critical
Publication of JP7784430B2 publication Critical patent/JP7784430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023537723A 2020-09-01 2021-09-01 新規化合物 Active JP7784430B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2013728.7 2020-09-01
GBGB2013728.7A GB202013728D0 (en) 2020-09-01 2020-09-01 Novel compounds
PCT/GB2021/052261 WO2022049376A1 (en) 2020-09-01 2021-09-01 Novel compounds

Publications (3)

Publication Number Publication Date
JP2023539694A JP2023539694A (ja) 2023-09-15
JP2023539694A5 JP2023539694A5 (cg-RX-API-DMAC10.html) 2024-09-09
JP7784430B2 true JP7784430B2 (ja) 2025-12-11

Family

ID=72749708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537723A Active JP7784430B2 (ja) 2020-09-01 2021-09-01 新規化合物

Country Status (12)

Country Link
US (1) US12630516B2 (cg-RX-API-DMAC10.html)
EP (1) EP4208442B1 (cg-RX-API-DMAC10.html)
JP (1) JP7784430B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230069915A (cg-RX-API-DMAC10.html)
CN (1) CN116096705A (cg-RX-API-DMAC10.html)
AU (1) AU2021337195A1 (cg-RX-API-DMAC10.html)
CA (1) CA3190645A1 (cg-RX-API-DMAC10.html)
ES (1) ES3055772T3 (cg-RX-API-DMAC10.html)
GB (1) GB202013728D0 (cg-RX-API-DMAC10.html)
IL (1) IL300900A (cg-RX-API-DMAC10.html)
MX (1) MX2023002525A (cg-RX-API-DMAC10.html)
WO (1) WO2022049376A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202013731D0 (en) 2020-09-01 2020-10-14 Nrg Therapeutics Ltd Novel cmpounds
WO2023209651A1 (en) * 2022-04-29 2023-11-02 Dong-A St Co., Ltd. Bicycle compounds as tead inhibitor
GB202300833D0 (en) 2023-01-19 2023-03-08 Nrg Therapeutics Ltd Novel compounds
CN119306612B (zh) * 2023-07-14 2026-03-20 中国科学院大连化学物理研究所 一种反式氨基茚满的制备方法
CN121866248A (zh) 2023-09-05 2026-04-14 Nrg治疗有限公司 作为mptp抑制剂起作用的吡啶衍生物
GB202410534D0 (en) 2024-07-18 2024-09-04 Nrg Therapeutics Ltd Novel method and uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506852A (ja) 2008-10-27 2012-03-22 コンジェニア・エッセエッレエッレ ミトコンドリアの膜透過性遷移の阻害剤として有用なアクリルアミド誘導体
WO2012102405A1 (ja) 2011-01-28 2012-08-02 佐藤製薬株式会社 縮環化合物
JP2017538699A (ja) 2014-12-05 2017-12-28 エーエヌ2エイチ ディスカバリー リミテッド パーキンリガーゼ活性化の方法及び組成物
JP2023539695A (ja) 2020-09-01 2023-09-15 エヌアールジー セラピューティクス エルティーディー 新規化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2852659B2 (ja) * 1988-03-03 1999-02-03 富山化学工業株式会社 ピペラジン誘導体およびその塩
JPWO2003020313A1 (ja) 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−1−リン酸受容体調節剤からなる呼吸器疾患治療剤
AU2002354476A1 (en) 2001-12-14 2003-06-30 Japan Tobacco Inc. Pyrazolopyridine derivatives and medicinal use thereof
JP2006512306A (ja) * 2002-08-29 2006-04-13 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション アリール及びヘテロアリールプロペンアミド、それらの誘導体並びにそれらの治療用途
JP2006160916A (ja) * 2004-12-08 2006-06-22 Fuji Photo Film Co Ltd インクジェット用インク組成物及びインクジェット記録方法
JP5495206B2 (ja) 2006-10-24 2014-05-21 コンジエニア・ソシエタ・ア・レスポンサビリタ・リミタータ 変性性組織障害をmptの阻害により防止するための薬剤としてのフェニル置換マレイミド
WO2011087051A1 (ja) 2010-01-14 2011-07-21 国立大学法人金沢大学 S1p2受容体アンタゴニストを含む粥状動脈硬化治療薬
JP2017538676A (ja) 2014-11-05 2017-12-28 ザ ユニバーシティ オブ カンザス ミトコンドリア透過性遷移孔(mtPTP)の小分子阻害剤
CA2884607A1 (en) 2015-03-11 2016-09-11 Stealth Peptides International, Inc. Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions
WO2019002624A1 (de) 2017-06-30 2019-01-03 Kleuser, Burkhard Mittel zur therapie entzündlicher darmerkrankungen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506852A (ja) 2008-10-27 2012-03-22 コンジェニア・エッセエッレエッレ ミトコンドリアの膜透過性遷移の阻害剤として有用なアクリルアミド誘導体
WO2012102405A1 (ja) 2011-01-28 2012-08-02 佐藤製薬株式会社 縮環化合物
JP2017538699A (ja) 2014-12-05 2017-12-28 エーエヌ2エイチ ディスカバリー リミテッド パーキンリガーゼ活性化の方法及び組成物
JP2023539695A (ja) 2020-09-01 2023-09-15 エヌアールジー セラピューティクス エルティーディー 新規化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAPLUS(STN)[online],1980年,レコード番号(AN):1981:78266;CAS 登録番号:76381-38-9, 76381-39-0, 76381-40-3
REGISTRY (STN) [online],2011.03.13 [検索日 2025.05.08] CAS登録番号 1268319-90-9

Also Published As

Publication number Publication date
JP2023539694A (ja) 2023-09-15
WO2022049376A1 (en) 2022-03-10
US12630516B2 (en) 2026-05-19
MX2023002525A (es) 2023-05-17
KR20230069915A (ko) 2023-05-19
CN116096705A (zh) 2023-05-09
EP4208442B1 (en) 2025-10-22
EP4208442A1 (en) 2023-07-12
US20240067614A1 (en) 2024-02-29
ES3055772T3 (en) 2026-02-16
CA3190645A1 (en) 2022-03-10
GB202013728D0 (en) 2020-10-14
AU2021337195A1 (en) 2023-03-02
IL300900A (en) 2023-04-01
EP4208442C0 (en) 2025-10-22

Similar Documents

Publication Publication Date Title
JP7784431B2 (ja) 新規化合物
JP2023539694A (ja) 新規化合物
EP3786162B1 (en) Bipyrazole derivatives as jak inhibitors
WO2020238791A1 (zh) 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
JP2025508898A (ja) アクリルアミド化合物
CN118908962A (zh) 作为hpk1的降解剂的异双功能化合物
JP2026503519A (ja) mPTPの阻害剤
WO2024179393A1 (zh) 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用
HK40103736A (en) Bipyrazole derivatives as jak inhibitors
HK40087858A (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
HK40087858B (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
HK40049209B (en) Bipyrazole derivatives as jak inhibitors
HK40012259A (en) Bipyrazole derivatives as jak inhibitors
HK40012259B (en) Bipyrazole derivatives as jak inhibitors
NZ753637B2 (en) Bipyrazole derivatives as jak inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251201

R150 Certificate of patent or registration of utility model

Ref document number: 7784430

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150